0001772016-26-000012
SEC filingModest revenue growth (2% Q2) offset by operating profit decline (-31%) from higher costs and inventory charge; share repurchases continue.
For the six months ended March 31, 2026, BellRing Brands reported net sales of $1,136.0 million, up 1% from $1,120.9 million in the prior year. The increase was primarily driven by volume growth in Premier Protein (+6%) and Dymatize (+10%), partially offset by lower average net selling prices due to promotional investment and unfavorable mix. Operating profit declined 31% to $144.5 million from $210.4 million, pressured by higher net product costs of $45.7 million (including an $11.3 million inventory charge for a substandard third-party ingredient), increased advertising expenses of $6.0 million, and lower net selling prices. These headwinds were partially offset by favorable changes in commodity derivative remeasurements ($31.4 million gain) and lower employee-related expenses ($6.8 million). Net earnings fell 43% to $77.6 million, and the effective tax rate rose to 25.7% from 24.5%.
Premier Protein, the largest brand, saw 6% volume growth in H1 but net sales increased less than 1% due to price/mix deterioration. Promotional activity and distribution gains drove volumes, but aggressive pricing and unfavorable product mix weighed on revenue growth. Dymatize posted 7% sales growth in H1, with 10% volume expansion from international markets, though average selling prices declined on unfavorable mix. In the second quarter alone, Dymatize sales fell 2% due to elasticities from prior price increases. The "all other" category contributed modest incremental revenue.
Management highlighted ongoing inflationary pressures from tariffs and global trade policies, which have increased input costs. Mitigation initiatives include pricing actions, cost optimization, and supply chain adjustments, but the impact may persist. The Middle East conflict is not expected to materially affect results. No specific financial guidance was provided, but the company expects positive operating cash flow over the next twelve months and maintains a $500 million revolving credit facility with $147.6 million available. Share repurchases remain a priority, with $124.4 million spent in H1. The asset-light model requires minimal capital expenditures (less than 1% of sales), and no significant capex is planned. Key risks include supply chain disruption, commodity volatility, and consumer demand softness.
Cash and cash equivalents decreased to $32.6M from $71.8M at September 30, 2025, largely due to share repurchases and debt repayments. Restricted cash dropped to $0.6M from $17.3M, reflecting lower cash collateral on derivative positions. Inventory surged 24% to $409.1M, driven by higher finished goods ($344.1M vs $242.0M), indicating potential demand buildup or supply chain actions. Total debt increased to $1,185.0M, with the revolving credit facility drawn to $350.0M (from $250.0M), and the interest rate on borrowings was 5.82%. Shareholders' deficit widened to -$497.8M due to treasury stock purchases.
The most significant commitment is the Joint Juice litigation. The company accrued $86.0M in other current liabilities as of March 31, 2026, related to proposed settlements. The New York Settlement requires an additional $17.2M upon final approval, and the Multistate Settlement requires $70.8M. No other purchase commitments or long-term supply agreements were disclosed in the notes.
Share repurchases were aggressive: $124.4M for 4.2M shares in H1 2026 (average price $29.18), compared to $183.7M for 2.5M shares in H1 2025 (avg $71.98). The buyback pace accelerated in Q2 2026 (1.2M shares at $22.11). Debt financing supported these repurchases: net debt increased by $100M via revolving credit facility borrowings. No dividends were declared. Capital expenditures were minimal ($6.0M in H1 2026) but not separately disclosed in notes; only from cash flow statement.
The company operates as a single reportable segment. Revenue is derived from two product categories: shakes ($931.1M in H1 2026, 81.9% of total) and powders ($176.3M, 15.5%), with other products ($28.6M, 2.5%). No geographic breakdown was provided in the notes. The CODM evaluates performance using consolidated net earnings.
Operating cash flow (CFO) of ($14.3M) significantly deteriorated from $51.2M in the prior-year period, driven by a large working capital build—receivables increased $49.1M, inventories $79.1M, and prepaids/other current assets rose $0.4M. Accounts payable provided a partial offset of $35.4M. Net income was $77.6M, but non-cash adjustments (depreciation $9.8M, stock comp $11.2M, deferred taxes $14.6M, unrealized gain on derivatives ($28.9M)) and the working capital drag caused the negative CFO.
Capital expenditures (capex) more than tripled to $6.0M (vs $1.9M), reflecting increased investment in property, plant, and equipment. Computed free cash flow (CFO minus capex) was ($20.3M), compared to $49.3M in the prior year.
Financing activities used $35.5M, driven by $127.2M in treasury stock purchases and $8.3M in tax withholding payments, partially offset by net debt proceeds of $100.0M (proceeds $265M less repayments $165M). The company did not pay dividends.
Overall, the cash flow profile shows heavy working capital consumption and aggressive share repurchases, leading to a net cash outflow of $55.9M for the period. The negative CFO and capex suggest the company relied on debt and cash reserves to fund operations and shareholder returns.